Brivekimig Trial for Hidradenitis Suppurativa
Phase 2
188
about 2.5 years
18+
11 sites in CA, FL, GA +6
About this study
This trial is testing a treatment called brivekimig in people with moderate to severe hidradenitis suppurativa. The goal is to see if brivekimig helps treat HS and how safe it is.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Brivekimig
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Change from Baseline in Dermatology Life Quality Index (DLQI) total score at Week 16., Change from Baseline in Hidradenitis Suppurativa Quality of Life (HiSQOL) total score at Week 16., Change from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 16, Change from Baseline in draining tunnel count at Week 16., Number of participants with treatment-emergent adverse events (TEAE), serious adverse events (SAE) and laboratory anomalies., Percentage of participants achieving response on the Hidradenitis Suppurativa Skin Pain Numeric Rating Scale from the HS Symptom Assessment Questionnaire (HS-SAQ skin pain NRS) at week 8